Aprogen Biologics Balance Sheet Health
Financial Health criteria checks 1/6
Aprogen Biologics has a total shareholder equity of ₩368.7B and total debt of ₩161.4B, which brings its debt-to-equity ratio to 43.8%. Its total assets and total liabilities are ₩589.4B and ₩220.7B respectively.
Key information
43.8%
Debt to equity ratio
₩161.36b
Debt
| Interest coverage ratio | n/a |
| Cash | ₩10.05b |
| Equity | ₩368.69b |
| Total liabilities | ₩220.71b |
| Total assets | ₩589.40b |
Recent financial health updates
Recent updates
More Unpleasant Surprises Could Be In Store For Aprogen Biologics Inc.'s (KRX:003060) Shares After Tumbling 28%
Apr 18
We Wouldn't Rely On Aprogen pharmaceuticalsInc's (KRX:003060) Statutory Earnings As A Guide
Jan 16Aprogen pharmaceuticals,Inc.'s (KRX:003060) Financials Are Too Obscure To Link With Current Share Price Momentum: What's In Store For the Stock?
Dec 20
Is Aprogen pharmaceuticalsInc (KRX:003060) A Risky Investment?
Nov 24Financial Position Analysis
Short Term Liabilities: A003060's short term assets (₩84.9B) do not cover its short term liabilities (₩157.9B).
Long Term Liabilities: A003060's short term assets (₩84.9B) exceed its long term liabilities (₩62.8B).
Debt to Equity History and Analysis
Debt Level: A003060's net debt to equity ratio (41%) is considered high.
Reducing Debt: A003060's debt to equity ratio has increased from 25.3% to 43.8% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Insufficient data to determine if A003060 has enough cash runway based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if A003060 has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.